Age-Related Macular Degeneration Market to Reach USD 26.9 Billion by 2036, Driven by Expanding Anti-VEGF Adoption and Geographic Atrophy Therapies

The global Age-Related Macular Degeneration (AMD) Market is poised for steady growth as rising life expectancy, increasing prevalence of retinal disorders, and ongoing innovation in ophthalmology therapeutics continue to drive demand. According to Fact.MR analysis, the market was valued at USD 13.1 billion in 2025 and is projected to grow from USD 13.9 billion in 2026 to USD 26.9 billion by 2036, registering a CAGR of 6.8% during the forecast period.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=7976

The market is benefiting from widespread adoption of anti-VEGF therapies for wet AMD and the emergence of approved treatments for geographic atrophy, creating new revenue opportunities across the retinal disease treatment landscape.

Market Highlights

• Market size estimated at USD 13.9 billion in 2026
• Forecast to reach USD 26.9 billion by 2036
• Expected CAGR of 6.8% from 2026 to 2036
• Wet AMD projected to account for 64.0% market share in 2026
• Eylea and Eylea HD expected to hold 35.0% share
• Anti-VEGF therapies projected to represent 76.0% share
• Hospital pharmacies forecast to capture 51.0% share
• Ophthalmology clinics expected to account for 47.0% share
• United States projected to be the leading growth market among major countries at 6.7% CAGR

Market Overview

Age-related macular degeneration remains one of the leading causes of vision impairment among older adults worldwide. The growing global elderly population is increasing demand for retinal screening, diagnosis, and treatment services. While wet AMD continues to generate substantial treatment demand through recurring anti-VEGF injections, the introduction of therapies targeting geographic atrophy is expanding the treatment landscape for advanced dry AMD patients.

Healthcare providers are increasingly focused on earlier diagnosis, improved patient adherence, and longer-acting therapies that reduce treatment burden while maintaining visual outcomes.

Analyst Perspective

"AMD treatment demand is becoming increasingly therapy-specific. Retina specialists seek durable efficacy, practical dosing schedules, and improved patient adherence. Companies that combine strong clinical evidence with patient access support are likely to maintain long-term market leadership."

Competitive Landscape

Competition in the AMD market is centered on treatment efficacy, dosing frequency, patient outcomes, and reimbursement support. Leading pharmaceutical companies continue investing in next-generation retinal therapies designed to reduce injection frequency and improve patient convenience.

Key market participants include:

• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Bayer AG
• Novartis AG

The market is also witnessing increasing focus on geographic atrophy treatments, creating a new competitive segment beyond traditional wet AMD therapies.

Production, Supply Chain, and Procurement Analysis

The AMD treatment value chain includes drug discovery, biologics manufacturing, regulatory approval, specialty distribution, hospital procurement, and specialist administration. Because most AMD therapies are injectable biologics, maintaining cold-chain integrity and uninterrupted supply remains critical.

Healthcare providers increasingly prioritize:

• Reliable product availability
• Reimbursement assistance programs
• Clinical evidence supporting visual outcomes
• Longer dosing intervals
• Cost-effectiveness and patient adherence

Manufacturers that combine clinical performance with strong access programs are expected to gain competitive advantages in both developed and emerging markets.

Country Opportunity Assessment

United States
The United States is projected to grow at 6.7% CAGR through 2036, supported by widespread anti-VEGF utilization, strong reimbursement infrastructure, and increasing adoption of geographic atrophy therapies.
China
China is forecast to expand at 6.5% CAGR, driven by improving hospital-based retinal care, increasing patient awareness, and growing access to specialist ophthalmology services.
United Kingdom
The UK market is expected to register 6.3% CAGR, supported by structured retinal care pathways and continued investment in specialist eye care services.
India
India is projected to grow at 6.1% CAGR, benefiting from expanding hospital infrastructure, improved retinal disease screening, and increasing availability of specialist treatment centers.
South Korea, Germany, and Japan
South Korea, Germany, and Japan are expected to witness stable growth as aging populations, established ophthalmology networks, and access to advanced therapies support market expansion.

Explore the Full Research Study & Forecast: https://www.factmr.com/report/age-related-macular-degeneration-market

Technology and Innovation Outlook

Innovation remains a key growth driver across the AMD treatment landscape. Major industry developments include:

• Longer-acting anti-VEGF therapies
• High-dose retinal biologics
• Geographic atrophy treatments
• Advanced retinal imaging technologies
• AI-assisted diagnosis and screening tools
• Personalized treatment approaches

The shift toward therapies requiring fewer injections is expected to improve patient compliance while reducing pressure on retinal clinics and healthcare systems.

Future Outlook

The AMD market is expected to maintain strong momentum through 2036 as aging populations increase the burden of retinal disease globally. Continued advancements in biologics, retinal imaging, and geographic atrophy therapies will create new opportunities for pharmaceutical companies, healthcare providers, and investors.

Organizations that successfully address treatment burden, improve patient access, and demonstrate long-term vision preservation benefits will be best positioned to capture future market growth.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/checkout/7976

Explore In-Depth Healthcare Market Insights: https://www.factmr.com/industry/healthcare

To View Related Report:

Veterinary Wound Sprays Market https://www.factmr.com/report/997/veterinary-wound-sprays-market
Fibrosarcoma Market https://www.factmr.com/report/353/fibrosarcoma-market
Membrane Protein Characterization Services Market https://www.factmr.com/report/3410/membrane-protein-characterization-service-market
Medical Marker Bands Market https://www.factmr.com/report/4364/medical-marker-bands-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.